30 closest matches · ranked by relevance
Abdominal Fat
Primary: Difference in Circumferential Measurement Related to Sham and Therapeutic Group at 12 Weeks Post-treatment — 1.9; 0 cm
Body Fat
Primary: Change of Thigh Circumference From Baseline — .98; .32 cm
Circumference Reduction
Primary: Change in Combined Circumference Measurements — -5.36 inches — p=<.0001
Circumference Reduction
Primary: Circumference Change in the Thighs at the 12-week Follow-up Compared to Baseline Measurements — -2.8 centimeter
Body Contouring
Primary: Change in Combined Upper Arm Circumference Measurements From Baseline to Endpoint — 18; 1 participants
Abdominal Subcutaneous Fat
Primary: Waist Circumference Change — -2.03 Inches
Excess Abdominal Fat
Primary: Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound — -10.5 percentage change
Obesity
Primary: Difference in the Proportion of Primary Outcome Successes Between Treatment Groups for Change in Combined Circumference Measurements — 20; 3 participants — p=<0.00005
Fat Disorder
Primary: Change in Fat Thickness at Final Follow-up Compared to Baseline — -1.76 millimeters
Dermatological Non-Disease
Primary: Change in Waist Circumference — -1.87 cm — p=<0.0001
Circumference Reduction of Abdomen
Primary: Evaluation of Change in Abdomen Circumference Using Tape Measurements in cm at the 3 Months Follow-up Visit Comparing to Baseline. — 89.5 CM
Body Fat Disorder
Primary: Safety of the Zeltiq System for Non-invasive Fat Reduction in Subjects With Greater Flank Curvature. — 0; 0 UADEs
Weight Loss
Primary: Change in Weight — -0.5; -0.9; -0.6 Kg — p=0.723
Body Fat Disorder
Primary: Percentage of Pre-Treatment Images Correctly Identified by Reviewers — 90.5 percentage of correct identifications
Body Fat Disorder
Primary: Safety of the Zeltiq CoolSculpting System in the Outer Thighs — 8; 0 events
Skin Laxity · Lipodystrophy
Primary: Number of Participants With a Reduction of Submental Skin Area ≥ 20 mm^2 — 49 Participants
Skin Laxity · Lipodystrophy
Primary: Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale — 2 Participants
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
Body Fat Disorder
Primary: Proportion of Pre-treatment Images Correctly Identified — 32 photos
Abdominal Obesity
Primary: Waist Circumference — 87.0; 89.4 cm
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Body Fat Disorder
Primary: Change in the Fat Layer of the Treated Area as Measured by Ultrasound The Change in Fat Layer Thickness in the Treated Outer Thigh — -0.25 cm
Body Fat Disorder
Primary: Safety of CoolScupting in the Submental Area — 4 incidence of device- and/or procedure AE
Surgical Incision
Primary: Patient and Observer Scar Assessment Scale (POSAS)- Patient Scores 12M — 1.09; 1.22; 1.3; 1.87 score on a scale
Circumcision
Primary: Intraoperative Duration — 22.6; 13.0; 25.0; 28.6 minutes
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos
Body Fat Disorder
Primary: Percentage of Accurately Identified Pre-treatment Photos — 33; 23; 50; 23 photos
Circumcision
Primary: Intraoperative Duration — 9.0; 22.6 Min
Body Fat Disorder
Primary: The Number of Device and/or Procedure-Related Adverse Events — 12 device or procedure-related AEs
Circumference Reduction
Primary: Lay End User Ability to Correctly Choose Suitably Qualified Individuals to Get the ZERONA Z6 Treatments — 22 participants